Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · The Lancet · 891 citations
https://doi.org/10.1016/s0140-6736(23)00727-4